Rigel Pharmaceuticals | RIGL - Gross Profit On Sales


Rigel Pharmaceuticals reported $28.49M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Agenus USD 33.74M 468K Mar/2026
Amgen USD 5.87B 1.02B Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 75.25M 1.52M Jun/2026
AstraZeneca USD 12.86B 251M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Celldex Therapeutics USD 15K 106K Mar/2026
Daiichi Sankyo JPY 287.15B 152.68B Mar/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Veracyte USD 108.55M 7.39M Jun/2026